Valuation: Cell Source, Inc.

Market Cap 24.41M 21.09M 19.84M 18.04M 33.93M 2.34B 34.47M 233M 91.07M 1.17B 91.65M 89.65M 3.9B P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 34.92M 30.17M 28.38M 25.81M 48.54M 3.34B 49.32M 333M 130M 1.67B 131M 128M 5.57B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day+2.50%
1 week-0.40%
Current month-7.87%
1 month-4.65%
6 months-3.53%
Current year+64.00%
1 week 0.25
Extreme 0.25
0.82
1 month 0.25
Extreme 0.25
0.9
Current year 0.25
Extreme 0.25
2.25
1 year 0.25
Extreme 0.25
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 30/06/2014
Director TitleAgeSince
Chairman 77 18/05/2015
Director/Board Member 82 25/03/2021
Director/Board Member 72 10/03/2022
Date Insider Type Main position Quantity % Market Cap.
8/9/21 A Others

Director

800,000 2.4492%
6/30/21 A Others

Director

4,860 0.0149%
6/30/21 A Others

Chairman

2,976 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%-0.40%+133.62%+30,270.37% 44.02M
+0.17%+3.62%+70.94%+109.68% 73.25B
+1.73%+13.43%+57.10%+90.54% 61.95B
+0.11%-4.67%+0.52%+484.71% 28.02B
+5.24%+5.33%+57.01%+17.77% 24.15B
+1.26%-0.05%-18.30%-18.08% 23.01B
-0.71%+5.26%+241.94%+427.03% 18.35B
0.00%+5.62%+40.50%-15.26% 19.46B
+3.83%+2.65%+25.00%+592.85% 15.92B
+1.53%+0.30%+38.66%+152.95% 12.96B
Average +1.57%+1.11%+64.70%+3,211.26% 27.71B
Weighted average by Cap. +1.25%+3.43%+57.15%+171.52%

Financials

2023 2024
Net sales - -
Net income -5.32M -4.6M -4.32M -3.93M -7.4M -509M -7.52M -50.73M -19.85M -255M -19.98M -19.54M -849M -4.51M -3.9M -3.67M -3.33M -6.27M -432M -6.37M -43.02M -16.84M -216M -16.94M -16.57M -720M
Net Debt 9.27M 8.01M 7.54M 6.85M 12.89M 887M 13.1M 88.42M 34.6M 444M 34.82M 34.06M 1.48B 10.51M 9.08M 8.54M 7.77M 14.61M 1.01B 14.84M 100M 39.2M 504M 39.45M 38.59M 1.68B
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
-
Date Price Change Volume
17/08/26 $0.6479 +8.00% 1,700
14/08/26 $0.5999 -0.88% 5,508
13/08/26 $0.6052 +4.34% 3,914
  1. Stock Market
  2. Stocks
  3. CLCS Stock